Morgan Stanley raised the firm’s price target on Royalty Pharma (RPRX) to $64 from $63 and keeps an Overweight rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RPRX:
- Royalty Pharma price target raised to $58 from $50 at JPMorgan
- Royalty Pharma price target raised to $66 from $50 at Citi
- Royalty Pharma’s Earnings Call Signals Confident Growth
- Royalty Pharma price target raised to $57 from $51 at UBS
- Royalty Pharma: Leveraged Biopharma Catalysts and De-Risked Royalty Growth Support Further Upside